

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imugene Limited
ABN	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Paul Hopper
Date of last notice	23 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder)	KILINWATA INVESTMENTS PTY LTD <LIFE SCIENCE PORTFOLIO A/C> where the Director is a beneficiary.
Date of change	15 December 2025
No. of securities held prior to change	(1) 125,757 - Direct Shares ORDINARY FULLY PAID SHARES (2) 11,960,754 - Indirect Shares ORDINARY FULLY PAID SHARES (3) 85,785 - OPTIONS @ \$4.012 EXP 31/08/2026 (4) 85,295 - Employee Share Option Plan - Options (5) 136,266 - Employee Share Option Plan - Performance Rights
Class	(5) Performance Rights
Number acquired	(5) 124,054 Performance Rights
Number disposed	NIL
Value/Consideration	Performance Rights issued for NIL consideration under the Company's ESOP.
No. of securities held after change	(1) 125,757 - Direct Shares ORDINARY FULLY PAID SHARES (2) 11,960,754 - Indirect Shares ORDINARY FULLY PAID SHARES (3) 85,785 - OPTIONS @ \$4.012 EXP 31/08/2026 (4) 85,295 - Employee Share Option Plan - Options (5) 260,320 - Employee Share Option Plan - Performance Rights
Nature of change	(5) Issue of Performance Rights under the ESOP, as approved by shareholders at the Company's Annual General Meeting held on 13 November 2025.

⁺ See [chapter 19](#) for defined terms.

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imugene Limited
ABN	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Leslie Chong
Date of last notice	23 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	Ms Chong is a trustee of the Chong Super Fund TC Pty Ltd.
Date of change	15 December 2025
No. of securities held prior to change	(1) 2,618,782 - Direct ORDINARY FULLY PAID SHARES (2) 214,523 - Indirect ORDINARY FULLY PAID SHARES (3) 597,059 - Employee Share Option Plan - Options (4) 766,820 - Employee Share Option Plan - Performance Rights (5) 85,785 - OPTIONS @ \$4.012 EXP 31/08/2026
Class	(1) Direct ORDINARY FULLY PAID SHARES (2) Indirect ORDINARY FULLY PAID SHARES (3) Employee Share Option Plan - Options (4) Employee Share Option Plan - Performance Rights (5) OPTIONS @ \$4.012 EXP 31/08/2026
Number acquired	(4) 751,621 Employee Share Option Plan - Performance Rights
Number disposed	NIL
Value/Consideration	Performance Rights issued for NIL consideration under the Company's ESOP.
No. of securities held after change	(1) 2,618,782 - Direct ORDINARY FULLY PAID SHARES (2) 214,523 - Indirect ORDINARY FULLY PAID SHARES (3) 597,059 - Employee Share Option Plan - Options (4) 1,518,441 - Employee Share Option Plan - Performance Rights (5) 85,785 - OPTIONS @ \$4.012 EXP 31/08/2026

⁺ See [chapter 19](#) for defined terms.

Nature of change	(4) Issue of Performance Rights under the ESOP, as approved by shareholders at the Company's Annual General Meeting held on 13 November 2025.
-------------------------	---

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imugene Limited
ABN	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Lesley Russell
Date of last notice	18 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	15 and 17 December 2025
No. of securities held prior to change	(1)609,945 - Ordinary Fully Paid Shares (2)17,648 - Employee Share Option Plan - Options (3)73,530 - Restricted Stock Units (RSUs) (4)7,003 - OPTIONS@ \$4.012 EXP 31/08/2026
Class	(1) Ordinary Fully Paid Shares (3) Restricted Stock Units (RSUs)
Number acquired	(1) 14,706 Ordinary Fully Paid Shares (3) 29,411 RSUs
Number disposed	(3) 14,706 RSUs
Value/Consideration	(1) Ordinary Fully Paid Shares issued upon conversion of RSUs for NIL consideration. (3) RSUs issued for NIL consideration.
No. of securities held after change	(1)624,651 - Ordinary Fully Paid Shares (2)17,648 - Employee Share Option Plan - Options (3)88,235 - Restricted Stock Units (RSUs) (4)7,003 - OPTIONS@ \$4.012 EXP 31/08/2026

⁺ See [chapter 19](#) for defined terms.

Nature of change	<p>(1) Conversion of RSUs to ordinary fully paid shares upon vesting.</p> <p>(3) Restricted Stock Units issued under the ESOP and as approved by shareholders at the Company's Annual General Meeting held on 13 November 2025 and conversion to ordinary fully paid shares upon vesting.</p>
-------------------------	---

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imugene Limited
ABN	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Kim Drapkin
Date of last notice	18 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	15 and 17 December 2025
No. of securities held prior to change	(1) 18,208 - Ordinary Fully Paid Shares (2) 3,502 - OPTIONS @ \$4.012 EXP 31/08/2026 (3) 73,530 - Restricted Stock Units (RSUs)
Class	(1) 18,208 - Ordinary Fully Paid Shares (3) Restricted Stock Units (RSUs)
Number acquired	(1) 14,706 Ordinary Fully Paid Shares (3) 29,411 RSUs
Number disposed	(3) 14,706 RSUs
Value/Consideration	(1) Ordinary Fully Shares issued upon conversation of RSUs for NIL consideration. (3) Restricted Stock Units issued for NIL consideration under the Company's ESOP.
No. of securities held after change	(1) 32,914 - Ordinary Fully Paid Shares (2) 3,502 - OPTIONS @ \$4.012 EXP 31/08/2026 (3) 88,235 - Restricted Stock Units (RSUs)

⁺ See [chapter 19](#) for defined terms.

Nature of change	(1) Conversion of RSUs to Ordinary Fully Paid shares upon vesting. (3) Issue of Restricted Stock Units under the ESOP, as approved by shareholders at the Company's Annual General Meeting held on 13 November 2025.
-------------------------	---

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imugene Limited
ABN	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Jakob Dupont
Date of last notice	18 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	15 and 17 December 2025
No. of securities held prior to change	(1) 17,332 - Ordinary Fully Paid Shares (2) 2,627 - OPTIONS @ \$4.012 EXP 31/08/2026 (3) 61,765 - Employee Share Option Plan - Options (4) 73,530 - Restricted Stock Units (RSUs)
Class	(1) Ordinary Fully Paid Shares (4) Restricted Stock Units (RSUs)
Number acquired	(1) 14,706 Ordinary Fully Paid Shares (4) 29,411 RSUs
Number disposed	(4) 14,706 RSUs
Value/Consideration	(1) Ordinary Fully Paid Shares issued upon conversion of RSUs for NIL consideration. (4) Restricted Stock Units issued for NIL consideration under the Company's ESOP.
No. of securities held after change	(1) 32,038 - Ordinary Fully Paid Shares (2) 2,627 - OPTIONS @ \$4.012 EXP 31/08/2026 (3) 61,765 - Employee Share Option Plan - Options (4) 88,235 - Restricted Stock Units (RSUs)

⁺ See [chapter 19](#) for defined terms.

Nature of change	(1) Conversion of RSUs to Ordinary Fully Paid Shares upon vesting. (4) Issue of Restricted Stock Units under the ESOP, as approved by shareholders at the Company's Annual General Meeting held on 13 November 2025.
-------------------------	---

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.